Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer

(2017) Thomas Powles et al.   JOURNAL OF CLINICAL ONCOLOGY

Oesophageal cancer

(2017) Jesper Lagergren et al.   LANCET

Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer

(2017) Gianluca Tomasello et al.   Expert Review of Clinical Pharmacology

Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer

(2017) Mohan Suntharalingam et al.   JAMA Oncology

Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma

(2016) Hiroo Imai et al.   CHEMOTHERAPY

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

(2016) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

(2015) Sylvie Lorenzen et al.   EUROPEAN JOURNAL OF CANCER

Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries

(2015) María José Domper Arnal   WORLD JOURNAL OF GASTROENTEROLOGY

The Global Burden of Cancer 2013

(2015) Christina Fitzmaurice et al.   JAMA Oncology

Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models

(2013) WENMIN HOU et al.   ONCOLOGY REPORTS

Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity

(2012) Kensuke Shiraishi et al.   Gastric Cancer

Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma

(2012) Xiao-Fang Guo   ONCOLOGY REPORTS

Targeted Therapies for Metastatic Esophagogastric Cancer

(2011) Deepa Reddy et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Optimal Therapeutic Strategies for Resectable Oesophageal or Oesophagogastric Junction Cancer

(2011) Branislav Bystricky et al.   DRUGS

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the human EGFR family in esophagogastric cancer

(2011) Alicia Okines et al.   Nature Reviews Clinical Oncology

A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy

(2010) Ken Kato et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

(2010) Z. A. Wainberg et al.   CLINICAL CANCER RESEARCH

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 Amplification

(2010) J. Tanizaki et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma

(2010) Kondo   ONCOLOGY REPORTS

Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

(2008) Henry L. Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY